CY1119599T1 - Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτων - Google Patents

Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτων

Info

Publication number
CY1119599T1
CY1119599T1 CY20171101189T CY171101189T CY1119599T1 CY 1119599 T1 CY1119599 T1 CY 1119599T1 CY 20171101189 T CY20171101189 T CY 20171101189T CY 171101189 T CY171101189 T CY 171101189T CY 1119599 T1 CY1119599 T1 CY 1119599T1
Authority
CY
Cyprus
Prior art keywords
thrombine
corruption
motors
binding
thrombin
Prior art date
Application number
CY20171101189T
Other languages
English (en)
Inventor
James Andrew HUNTINGTON
Trevor Baglin
Jonathan LANGDOWN
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of CY1119599T1 publication Critical patent/CY1119599T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Αυτή η εφεύρεση σχετίζεται με απομονωμένα αντισώματα τα οποία αναγνωρίζουν τον επίτοπο εξωσημείου 1 της θρομβίνης και αναστέλλουν επιλεκτικώς θρομβίνη άνευ προαγωγής αιμορραγίας. Αυτά τα μόρια αντισωμάτων μπορεί να είναι χρήσιμα στην αγωγή και πρόληψη της θρόμβωσης, του εμβολισμού και άλλων καταστάσεων που μεσολαβούνται από θρομβίνη.
CY20171101189T 2011-12-14 2017-11-14 Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτων CY1119599T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1121513.4A GB201121513D0 (en) 2011-12-14 2011-12-14 Thrombin-binding antibody molecules and uses thereof
PCT/GB2012/053140 WO2013088164A1 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof

Publications (1)

Publication Number Publication Date
CY1119599T1 true CY1119599T1 (el) 2018-04-04

Family

ID=45560465

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101189T CY1119599T1 (el) 2011-12-14 2017-11-14 Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτων

Country Status (33)

Country Link
US (5) US9518129B2 (el)
EP (2) EP2791177B1 (el)
JP (2) JP6216954B2 (el)
KR (1) KR102114506B1 (el)
CN (2) CN104053673B (el)
AU (2) AU2012351858B2 (el)
BR (1) BR112014014605A2 (el)
CA (1) CA2856656C (el)
CO (1) CO7101192A2 (el)
CY (1) CY1119599T1 (el)
DK (1) DK2791177T3 (el)
ES (1) ES2642718T3 (el)
GB (1) GB201121513D0 (el)
HK (2) HK1202564A1 (el)
HR (1) HRP20171775T1 (el)
HU (1) HUE034793T2 (el)
IL (1) IL232797B (el)
LT (1) LT2791177T (el)
ME (1) ME02901B (el)
MX (1) MX353281B (el)
MY (1) MY170980A (el)
NO (1) NO2791177T3 (el)
PE (2) PE20190171A1 (el)
PH (1) PH12014501169A1 (el)
PL (1) PL2791177T3 (el)
PT (1) PT2791177T (el)
RS (1) RS56510B1 (el)
RU (2) RU2642276C2 (el)
SG (1) SG11201402560WA (el)
SI (1) SI2791177T1 (el)
UA (1) UA116531C2 (el)
WO (1) WO2013088164A1 (el)
ZA (1) ZA201403836B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201310949D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Binding Motif
GB201310948D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Screening methods
CN107043423B (zh) * 2016-02-05 2021-02-26 江苏恒瑞医药股份有限公司 凝血酶抗体、其抗原结合片段及医药用途
WO2017133673A1 (zh) * 2016-02-05 2017-08-10 江苏恒瑞医药股份有限公司 凝血酶抗体、其抗原结合片段及医药用途
WO2018081534A1 (en) * 2016-10-28 2018-05-03 President And Fellows Of Harvard College Assay for exo-site binding molecules
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
WO2020003077A1 (en) * 2018-06-25 2020-01-02 Janssen Pharmaceutica Nv Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68908175T2 (de) * 1988-05-27 1994-03-03 Centocor Inc Gefriergetrocknete formulierung für antikörperprodukte.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
WO1991017258A1 (en) 1990-05-10 1991-11-14 Cetus Corporation Inhibitors of factor xii activation and applications thereof
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5443827A (en) * 1993-05-03 1995-08-22 President And Fellows Of Harvard College Fibrin-targeted inhibitors of thrombin
AU1378495A (en) * 1993-12-27 1995-07-17 Hamilton Civic Hospitals Research Development, Inc. Methods and compositions for inhibiting thrombogenesis
GB9613718D0 (en) 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
AU5903000A (en) 1999-06-29 2001-01-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel anti-thrombin peptide
CA2378473A1 (en) 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation of platelet activation
WO2001087339A1 (en) * 2000-05-15 2001-11-22 Smithkline Beecham Corporation Antithrombotic agents
AU2001286900A1 (en) 2000-08-31 2002-03-13 Cor Therapeutics, Inc. Therapeutics and diagnostics based on a novel signal transduction system in platelets
US7615527B2 (en) * 2001-07-06 2009-11-10 Oregon Health & Science University Peptides which modulate blood coagulation and methods of use thereof
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
MEP0208A (xx) 2005-08-26 2010-02-10 Archemix Corp Aptameri koji vezuje trombin sa visokim afininitetom
US20100158890A1 (en) 2006-03-15 2010-06-24 Kenichi Tanaka Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
EP2297207B1 (en) 2008-06-19 2018-10-03 Prothix BV Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
WO2010033167A2 (en) 2008-09-18 2010-03-25 Archemix Corp. Anti-thrombin aptamer formulations and methods for use
US9518127B2 (en) 2011-07-22 2016-12-13 Csl Behring Gmbh Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof

Also Published As

Publication number Publication date
JP2015501830A (ja) 2015-01-19
SI2791177T1 (en) 2018-03-30
GB201121513D0 (en) 2012-01-25
JP2018039798A (ja) 2018-03-15
UA116531C2 (uk) 2018-04-10
CO7101192A2 (es) 2014-10-31
EP2791177B1 (en) 2017-09-06
ES2642718T3 (es) 2017-11-17
US10287363B2 (en) 2019-05-14
US9988463B2 (en) 2018-06-05
PH12014501169B1 (en) 2014-09-08
MY170980A (en) 2019-09-23
US20140370008A1 (en) 2014-12-18
RU2642276C2 (ru) 2018-01-24
MX2014007170A (es) 2015-04-17
BR112014014605A2 (pt) 2017-06-13
EP2791177A1 (en) 2014-10-22
US20180334511A1 (en) 2018-11-22
HK1202564A1 (en) 2015-10-02
CN104053673B (zh) 2018-01-12
US20210371543A1 (en) 2021-12-02
PT2791177T (pt) 2017-11-29
WO2013088164A1 (en) 2013-06-20
HRP20171775T1 (hr) 2017-12-29
AU2012351858B2 (en) 2017-10-05
MX353281B (es) 2018-01-08
US20190276558A1 (en) 2019-09-12
HK1246326A1 (zh) 2018-09-07
IL232797A0 (en) 2014-07-31
IL232797B (en) 2018-07-31
PE20141706A1 (es) 2014-11-13
HUE034793T2 (en) 2018-02-28
PH12014501169A1 (en) 2014-09-08
RU2014124985A (ru) 2016-02-10
ME02901B (me) 2018-04-20
US9518129B2 (en) 2016-12-13
NZ625386A (en) 2017-03-31
US20170066842A1 (en) 2017-03-09
JP6216954B2 (ja) 2017-10-25
EP3275903A1 (en) 2018-01-31
JP6705785B2 (ja) 2020-06-03
LT2791177T (lt) 2017-11-27
RU2017144629A3 (el) 2021-04-05
DK2791177T3 (en) 2017-12-18
NO2791177T3 (el) 2018-02-03
PL2791177T3 (pl) 2018-03-30
AU2012351858A1 (en) 2014-06-12
ZA201403836B (en) 2015-12-23
CA2856656C (en) 2021-01-19
PE20190171A1 (es) 2019-02-01
RU2017144629A (ru) 2019-02-18
SG11201402560WA (en) 2014-06-27
CN104053673A (zh) 2014-09-17
KR102114506B1 (ko) 2020-05-22
AU2017268655A1 (en) 2017-12-21
AU2017268655B2 (en) 2019-05-09
KR20140105556A (ko) 2014-09-01
CA2856656A1 (en) 2013-06-20
CN107936119A (zh) 2018-04-20
CN107936119B (zh) 2021-06-15
RS56510B1 (sr) 2018-02-28

Similar Documents

Publication Publication Date Title
CY1119599T1 (el) Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτων
CY1121546T1 (el) Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου
CY1122478T1 (el) Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CY1119399T1 (el) Aντι-dkk-1 αντισωματα
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
EA201791485A1 (ru) Анти-cd47-антитела и их применения
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
CY1120557T1 (el) Μορια δεσμευσης anti-pseudomonas psl και χρησεις αυτων
EA201791550A1 (ru) Димеры бензодиазепинов, их конъюгаты и способы их получения и применения
EA201890321A1 (ru) Молекулы антител, которые связываются с cd45
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201690314A1 (ru) Анти-garp-белок и его применения
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
EA202193044A2 (ru) Способы лечения таупатии
EA201491644A1 (ru) Фармацевтические композиции
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1124360T1 (el) Αντισωματα aντι-il-33 και χρησεις αυτων
MX2016010360A (es) Moleculas de anticuerpo para el virus del dengue y uso de las mismas.